AOD-9604 vs Cagrilintide
Metabolic
AOD-9604
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
Metabolic
Cagrilintide
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
Side by side
| Dimension | AOD-9604 | Cagrilintide |
|---|---|---|
| Molecular weight A 2.4× difference in mass — these are not comparable on a milligram-for-milligram basis. | 1815.08 g/mol | 4409 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 221231-10-3 | 1415456-99-3 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg | 10mg |
| Entry price | $44 | $99 |
| Cost per mg | $8.80 | $9.90 |
Mechanism
AOD-9604
AOD-9604 corresponds to residues 176-191 of the somatotropin sequence, the C-terminal region studied in early work for activity on adipose tissue in vitro. The research premise is separation of function: retaining lipolytic activity in assays while excluding the IGF-1-mediated signaling of the full-length molecule. Reported results across models have been more modest than preclinical rodent data suggested — a gap worth knowing before designing around it.
Cagrilintide
Cagrilintide is an acylated analog of human amylin, the peptide co-secreted with insulin from pancreatic β-cells. It acts at the calcitonin receptor and amylin receptor subtypes, a pathway entirely separate from GLP-1 and GIP signaling. Research interest centers on whether amylin and incretin pathways are additive, which is why it appears frequently in combination studies alongside semaglutide.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
AOD-9604
Evidence base: thin and lopsided. Around eighteen indexed results, mostly anti-doping analytical chemistry. Metabolism and assay behaviour are better characterised than efficacy, and the clinical obesity programme did not progress.
Full research reference →Cagrilintide
Evidence base: strong and independently reported. Randomised phase 2 and phase 3 data in major journals, with a trial design that compares the combination against each component separately.
Full research reference →Research applications
AOD-9604
- Lipolysis and β-adrenergic pathway assays in adipocyte culture
- Comparative studies against full-length hGH
- IGF-1 independence verification studies
Cagrilintide
- Amylin and calcitonin receptor binding studies
- Combination pharmacology with incretin agonists
- Satiety signaling research in preclinical models
- Gastric emptying rate assays
Common questions
What is the difference between AOD-9604 and Cagrilintide?
AOD-9604 is c-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone. Cagrilintide is long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism. They differ in molecular weight (1815.08 vs 4409 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, AOD-9604 or Cagrilintide?
AOD-9604 is lower at approximately $8.80 per milligram at its best tier, against $9.90 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can AOD-9604 and Cagrilintide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should AOD-9604 and Cagrilintide be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Cagrilintide: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Which has the stronger evidence base?
AOD-9604 — Evidence base: thin and lopsided. Around eighteen indexed results, mostly anti-doping analytical chemistry. Metabolism and assay behaviour are better characterised than efficacy, and the clinical obesity programme did not progress. Cagrilintide — Evidence base: strong and independently reported. Randomised phase 2 and phase 3 data in major journals, with a trial design that compares the combination against each component separately.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.